Expert perspectives on tricuspid repair | replacement | medical therapy — Beyond the Guidelines: Insights from the cardiovascular research technologies 2026 meeting

Advancements in transcatheter tricuspid valve intervention (TTVI) technology have yielded meaningful improvements in quality-of-life (QOL) for patients with tricuspid regurgitation (TR). The recent Food and Drug Administration (FDA) approval of two TTVI devices, TriClip and EVOQUE, has prompted extensive discussion regarding patient selection, device preference, and optimal timing of intervention. A dedicated session titled “Beyond the Guidelines: Tricuspid repair, replacement, medical therapy” was convened to examine clinical scenarios not adequately addressed by existing guidelines. This review summarizes the key observations and expert panel discussion to identify evidence gaps and inform the framework for future guideline development.